⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting

Official Title: A Multi-center, Stratified Randomized, Controlled Study to Evaluate the Efficacy and Safety of Palonosetron Hydrochloride in the Prevention of Nausea and Vomiting Associated With Moderate and Highly Emetogenic Chemotherapy in China

Study ID: NCT01481831

Study Description

Brief Summary: This purpose of this study is to evaluate the efficacy and safety of single and repeated doses of palonosetron hydrochloride in preventing nausea and vomiting caused by moderate and highly emetogenic chemotherapy in patients.

Detailed Description: Group I (Highly Emetogenic Chemotherapy): Patients that accepted chemotherapy including Cisplatin≥50mg/m2, Carmustine\>250mg/m2, Cyclophosphamide\>1500mg/m2, Dacarbazine\>60mg/m2, Doxorubicin\>60mg/m2, Epirubicin\>90mg/m2, IFO≥10g/m2 or AC program. Group II (Moderately Emetogenic Chemotherapy): Patients that accepted chemotherapy including any dose of Carboplatin, Daunorubicin, Oaliplatin, Irinotecan, or Doxorubicin\<60mg/m2(not include liposomal doxorubicin), Epirubicin≤90mg/m2, Carmustine≤250mg/m2, Methotrexate≥250mg/m2, Cyclophosphamide≤1500mg/m2, Arabinoside\>200mg/m2, IFO\<10g/m2, Cisplatin≥50mg/m2. Total subjects: 1000, single dose of palonosetron group of 500 patients, repeated doses of palonosetron group of 500 patients. According to the study subjects receiving highly emetogenic chemotherapy or moderately emetogenic chemotherapy, subjects are stratified randomize.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Anhui Provincial Hospital, Hefei, Anhui, China

Chinese Academy of Medical Sciences Cancer Hospital, Beijing, Beijing, China

Chinese PLA 301 Hospital, Beijing, Beijing, China

Chinese PLA 307 Hospital, Beijing, Beijing, China

Chinese PLA Navy General Hospital, Beijing, Beijing, China

Fuzhou General Hospital of Nanjing Military Command, Fuzhou, Fujian, China

Guangxi Cancer Hospital, Nanning, Guangxi, China

The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

The First People's Hospital of Changzhou, Changzhou, Jiangsu, China

Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

The Fourth People's Hospital of Wuxi, Wuxi, Jiangsu, China

Shandong Cancer Hospital, Jinan, Shandong, China

Shandong Provincial Hospital, Jinan, Shandong, China

The Affiliated Hospital of Medical College Qingdao University, Qingdao, Shandong, China

Shanghai Changzheng Hospital, Shanghai, Shanghai, China

Shanghai Xinhua Hospital, Shanghai, Shanghai, China

Tangdu Hospital of Fourth Military Medical University, Xian, Shanxi, China

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: